ATE145007T1 - Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres - Google Patents
Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieresInfo
- Publication number
- ATE145007T1 ATE145007T1 AT89906932T AT89906932T ATE145007T1 AT E145007 T1 ATE145007 T1 AT E145007T1 AT 89906932 T AT89906932 T AT 89906932T AT 89906932 T AT89906932 T AT 89906932T AT E145007 T1 ATE145007 T1 AT E145007T1
- Authority
- AT
- Austria
- Prior art keywords
- monoclonal antibodies
- germs
- producing monoclonal
- free animal
- animal
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9723—Urokinase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Optics & Photonics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20625988A | 1988-06-13 | 1988-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE145007T1 true ATE145007T1 (de) | 1996-11-15 |
Family
ID=22765616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89906932T ATE145007T1 (de) | 1988-06-13 | 1989-06-12 | Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP0413763B1 (de) |
| AT (1) | ATE145007T1 (de) |
| AU (1) | AU642604B2 (de) |
| DE (1) | DE68927438T2 (de) |
| SG (1) | SG50681A1 (de) |
| WO (1) | WO1989012690A1 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5080883A (en) * | 1990-05-11 | 1992-01-14 | Mallinckrodt, Inc. | 99 mtcn3s-conjugated anti-bibrin monoclonal antibody as an in vivo diagnostic agent for imaging |
| US5750652A (en) * | 1994-01-21 | 1998-05-12 | Yale University | Deltex proteins |
| US5487892A (en) * | 1994-02-24 | 1996-01-30 | American Biogenetic Sciences, Inc. | Method for treating thrombotic disease using a fibrin specific monoclonal antibody |
| US5817768A (en) * | 1995-06-07 | 1998-10-06 | The New York Blood Center, Inc. | Monospecific antibodies against a subunit of fibrinogen |
| SK287323B6 (sk) | 1998-11-06 | 2010-07-07 | University Of Z�Rich | Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie |
| ATE511856T1 (de) | 2000-03-13 | 2011-06-15 | Cornell Res Foundation Inc | Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2 |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| AU2001271720A1 (en) | 2000-07-05 | 2002-01-14 | Rosetta Inpharmatics, Inc. | Methods and compositions for determining gene function |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| PT1456346E (pt) | 2001-02-20 | 2012-05-02 | Intrexon Corp | Novo sistema de expressão de genes induzido baseado no recetor de ecdisona / recetor x retinoide invertebrado |
| AU2002248500B2 (en) | 2001-02-20 | 2007-12-13 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| AU2002306550B2 (en) | 2001-02-20 | 2007-10-25 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| ES2392508T3 (es) | 2001-02-20 | 2012-12-11 | Intrexon Corporation | Receptores X retinoides quiméricos y su uso en un sistema inducible de expresión génica basado en receptores de ecdisona novedoso |
| US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
| MXPA04002808A (es) | 2001-09-26 | 2005-06-06 | Rheogene Holdings Inc | Acidos nucleicos receptores de ecdisona de mosca blanca, polipeptidos, y sus usos. |
| EP1436394A4 (de) | 2001-09-26 | 2004-12-29 | Rheo Gene Holdings Inc | Zikaden-ecdyson-rezeptor-nukleinsäuren, -polypeptide und ihre verwendungen |
| ATE441727T1 (de) | 2001-10-01 | 2009-09-15 | Sinai School Medicine | Noonansyndromgen |
| SI1535068T1 (sl) | 2002-08-13 | 2010-07-30 | N Dia Inc | Naprave in postopki za odkrivanje amnijske tekočine v vaginalnih izločkih |
| US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| WO2005070948A1 (en) | 2004-01-23 | 2005-08-04 | Intronn, Inc. | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| WO2007005898A2 (en) | 2005-07-05 | 2007-01-11 | Cornell Research Foundation, Inc. | Blocking leukocyte emigration and inflammation by interfering with cd99l2 |
| WO2007028147A2 (en) | 2005-09-01 | 2007-03-08 | Philadelphia Health & Education Corporation D.B.A. Drexel University College Of Medicin | Identification of a prostatic intraepithelial neoplasia (pin)-specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer |
| US8093043B2 (en) | 2008-06-04 | 2012-01-10 | New York University | β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis |
| US9140692B1 (en) | 2010-01-08 | 2015-09-22 | Glycozym, Inc. | Methods of identifying glycopeptides recognized by disease-associated auto-antibodies |
| EP2561355B1 (de) | 2010-04-20 | 2014-06-18 | Cornell University | Verfahren für die diagnose von melanozytenproliferationen |
| WO2014081633A1 (en) | 2012-11-20 | 2014-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Assay to measure midkine or pleiotrophin level for diagnosing a growth |
| EP4699616A2 (de) | 2013-01-02 | 2026-02-25 | Qiagen Sciences, LLC | Verfahren zur vorhersage der geburtszeit bei schwangeren frauen |
| NZ712167A (en) | 2013-03-15 | 2018-05-25 | Intrexon Corp | Boron-containing diacylhydrazines |
| AU2015317862A1 (en) | 2014-09-17 | 2017-04-06 | Intrexon Corporation | Boron-containing diacylhydrazine compounds |
| AU2016334401A1 (en) | 2015-10-10 | 2018-04-26 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| US10656164B2 (en) | 2016-12-22 | 2020-05-19 | Qiagen Sciences, Llc | Screening asymptomatic pregnant woman for preterm birth |
| US10935555B2 (en) | 2016-12-22 | 2021-03-02 | Qiagen Sciences, Llc | Determining candidate for induction of labor |
| WO2018203517A1 (ja) * | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立がん研究センター | プラスミンにより切断可能な抗不溶性フィブリン抗体と薬物とのコンジュゲート |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916070A (en) * | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
| WO1988001514A1 (en) * | 1986-08-25 | 1988-03-10 | American Biogenetic Sciences, Inc. | Monoclonal antibodies to fibrin |
-
1989
- 1989-06-12 SG SG1996008550A patent/SG50681A1/en unknown
- 1989-06-12 EP EP89906932A patent/EP0413763B1/de not_active Expired - Lifetime
- 1989-06-12 EP EP95202804A patent/EP0710720A1/de not_active Withdrawn
- 1989-06-12 WO PCT/US1989/002545 patent/WO1989012690A1/en not_active Ceased
- 1989-06-12 AT AT89906932T patent/ATE145007T1/de not_active IP Right Cessation
- 1989-06-12 DE DE68927438T patent/DE68927438T2/de not_active Expired - Fee Related
-
1992
- 1992-08-13 AU AU20976/92A patent/AU642604B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| SG50681A1 (en) | 1998-07-20 |
| DE68927438D1 (de) | 1996-12-12 |
| AU2097692A (en) | 1992-10-22 |
| EP0413763A4 (en) | 1991-09-25 |
| EP0710720A1 (de) | 1996-05-08 |
| EP0413763A1 (de) | 1991-02-27 |
| AU642604B2 (en) | 1993-10-21 |
| EP0413763B1 (de) | 1996-11-06 |
| DE68927438T2 (de) | 1997-03-20 |
| WO1989012690A1 (en) | 1989-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE145007T1 (de) | Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres | |
| DE58902737D1 (de) | Verfahren zur herstellung pharmazeutischer mischungen. | |
| DE3587360D1 (de) | Verfahren zur herstellung von chimaerischen monoklonalen antikoerpern. | |
| DE3382190D1 (de) | Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff. | |
| ATE297465T1 (de) | Verfahren zur herstellung von multivalenten antigenbindenden proteinen | |
| FI960268A7 (fi) | Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljint äantigeenin prekursorien ilmentymistä | |
| DE68902700D1 (de) | Verfahren zur herstellung von synthetischem schmieroel durch olefinoligomerisation. | |
| DE3789115D1 (de) | Verfahren zur herstellung eines optischen wellenleiters und erzeugnis. | |
| ATA901983A (de) | Verfahren zur herstellung eines monoklonalen antikoerpers | |
| DE3883129D1 (de) | Verfahren zur herstellung eines supraleitenden drahtes. | |
| ES548141A0 (es) | Un metodo para producir anticuerpos monoclonales especificospara proteina de tensioactivo alveolar de ser humano | |
| DE3584179D1 (de) | Verfahren zur herstellung eines insulinaehnlichen wachstumsfaktors i. | |
| DE3485054D1 (de) | Candida albicans zytoplasmaantigen, monoklonale antikoerper dagegen und verfahren zur herstellung. | |
| ATA191890A (de) | Verfahren zur herstellung hochfester loetverbindungen | |
| DE3878342D1 (de) | Verfahren zur herstellung eines agglomerierten schleifmittels. | |
| ATE73350T1 (de) | Verfahren zur tierischen wachstumsfoerderung. | |
| DE69001623D1 (de) | Verfahren zur herstellung von fluor-oxy-fluorsulfonylverbindungen durch direkte fluorierung von fluor-beta-sultonen. | |
| DE68902702D1 (de) | Verfahren zur herstellung von synthetischem schmieroel durch olefinoligomerisation. | |
| DE3880640D1 (de) | Verfahren zur herstellung aliphatischer o-arylurethane. | |
| FI973469A0 (fi) | Menetelmä tekijän IX valmistamiseksi biologisista lähteistä | |
| DE3869164D1 (de) | Zahnaerztliche stange mit diamantbeschichtung sowie verfahren zur herstellung. | |
| DE58902242D1 (de) | Verfahren zur herstellung von thymol. | |
| DE69630039D1 (de) | Verfahren zur herstellung gm2-spezifischer antikörper | |
| DE69114803D1 (de) | Verfahren zur herstellung eines oxideinkristalls. | |
| DE3580524D1 (de) | Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |